Literature DB >> 28500856

Effect of low-level laser therapy on tissue repair after dental extraction in rats administered zoledronic acid and dexamethasone.

João Batista Blessmann Weber1, Renata Stifelman Camilotti1, Juliana Jasper1, Liliane Cristina Onofre Casagrande1, Fábio Luiz Dal Moro Maito1.   

Abstract

Bisphosphonates (BPs) are being increasingly used for the treatment of metabolic and oncological pathologies involving the skeletal system. Because of the severity of the BP associated osteonecrosis of the jaws, the difficulties of treatment, and patient discomfort, additional support methods for their management are needed. Laser therapy has an easy handling, photobiostimulator effect on tissues healing, so it can be considered a preferred therapy. The aim of this study was to evaluate the influence of low-level laser therapy in the 685- and 830-nm wavelength in the healing process of the bone and soft tissues in rats under BP therapy [zoledronic acid (ZA)] and dexamethasone concomitantly that underwent a surgery for the extraction of upper molars. There were statistically significant differences in the clinical evaluation of the wound and the weight of the animals. Regarding the histological evaluation, it was possible to observe the different maturations of the healing stage between groups. The effect of drug therapy with ZA and dexamethasone in the bone tissue repair process induces osteonecrosis of the jaw in rats and slows down the healing process. In the laser groups, at the stipulated dosimetry, a positive influence on the bone and soft tissue repair process was observed.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28500856     DOI: 10.1117/1.JBO.22.5.058001

Source DB:  PubMed          Journal:  J Biomed Opt        ISSN: 1083-3668            Impact factor:   3.170


  2 in total

Review 1.  Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  J I Aguirre; E J Castillo; D B Kimmel
Journal:  Bone       Date:  2021-09-11       Impact factor: 4.398

2.  Zoledronic acid inhibits osteoclastogenesis and bone resorptive function by suppressing RANKL‑mediated NF‑κB and JNK and their downstream signalling pathways.

Authors:  Xiao-Lin Huang; Chao Liu; Xue-Mei Shi; Yu-Ting Cheng; Qian Zhou; Jian-Ping Li; Jian Liao
Journal:  Mol Med Rep       Date:  2021-12-22       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.